[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f1rqlnm6x5tmm1":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"proprietary_name":11,"non_proprietary_name":11,"is_proprietary":11,"active_ingredient":10,"administration_route":11,"available_strength":11,"dosage_form":11,"dose_schedule":11,"drug_unit":11,"is_available_generically":11,"mechanism_of_action":11,"overdosage":11,"warning":11,"species":12,"citations":14,"dose_schedules":29,"available_strengths":46,"label_statements":54,"drug_classes":77,"specialties":78,"medical_conditions":79,"animal_species":85},1620,"k22vgyyuitiqz8oi3ogpk3xs","oclacitinib","Oclacitinib",null,[13],"canine",[15,21,25],{"source":16,"licence":17,"source_url":18,"harvested_by":19,"retrieved_at":20},"EMA centrally authorised medicines","EMA reuse with attribution","https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fdocuments\u002Freport\u002Fmedicines-output-medicines-report_en.xlsx","load-reference-corpus.cjs","2026-09-07",{"source":22,"licence":23,"source_url":24,"harvested_by":19,"retrieved_at":20},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients",{"source":26,"licence":27,"source_url":28,"harvested_by":19,"retrieved_at":20},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[30,36,41],{"id":31,"dose_text":32,"species":33,"administration_route":34,"limitation":11,"source_label":35},11126,"The dose is 0.18 to 0.27 mg oclacitinib\u002Flb (0.4 to 0.6 mg oclacitinib\u002Fkg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy.","Dogs","Oral","apoquel® chewable",{"id":37,"dose_text":38,"species":33,"administration_route":34,"limitation":39,"source_label":40},11127,"Administer orally 0.18 to 0.27 mg\u002Fper pound of body weight (0.4 to 0.6 mg\u002Fkg body weight) twice daily for up to 14 days; then administered once daily for maintenance therapy.","APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches.\nThe use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents.\nDogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.","apoquel®",{"id":42,"dose_text":43,"species":11,"administration_route":44,"limitation":11,"source_label":45},11128,"The dose of APOQUEL (oclacitinib maleate) tablets is 0.18 to 0.27 mg oclacitinib\u002Flb (0.4 to 0.6 mg oclacitinib\u002Fkg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. APOQUEL may be administered with or without food.\nDosing Chart\nWeight Range\n(in lb)\nWeight Range\n(in Kg)\nNumber of Tablets to be Administered\nLow\nHigh\nLow\nHigh\n3.6 mg Tablets\n5.4 mg Tablets\n16 mg Tablets\n6.6\n9.9\n3.0\n4.4\n0.5\n-\n-\n10.0\n14.9\n4.5\n5.9\n-\n0.5\n-\n15.0\n19.9\n6.0\n8.9\n1\n-\n-\n20.0\n29.9\n9.0\n13.4\n-\n1\n-\n30.0\n44.9\n13.5\n19.9\n-\n-\n0.5\n45.0\n59.9\n20.0\n26.9\n-\n2\n-\n60.0\n89.9\n27.0\n39.9\n-\n-\n1\n90.0\n129.9\n40.0\n54.9\n-\n-\n1.5\n130.0\n175.9\n55.0\n80.0\n-\n-\n2","ORAL","apoquel",[47,51],{"id":48,"strength_text":49,"dosage_form":50,"proprietary_name":40,"species":33,"source_label":40},9763,"3.6, 5.4, or 16 mg of oclacitinib as oclacitinib maleate per tablet","Tablet",{"id":52,"strength_text":49,"dosage_form":53,"proprietary_name":35,"species":33,"source_label":35},9764,"Chewable Tablets",[55,59,62,67,70,73],{"id":56,"kind":57,"statement":58,"species":33,"limitation":39,"source_label":40},15996,"indication","Control of pruritus associated with\nallergic dermatitis and control of atopic dermatitis\nin dogs at least 12 months of age.",{"id":60,"kind":57,"statement":61,"species":11,"limitation":11,"source_label":45},15997,"Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.",{"id":63,"kind":64,"statement":65,"species":11,"limitation":11,"source_label":66},15998,"warning","APOQUEL CHEWABLE is not for use in dogs less than 12 months of age (see Animal Safety).\nAPOQUEL CHEWABLE modulates the immune system.\nAPOQUEL CHEWABLE is not for use in dogs with serious infections.\nAPOQUEL CHEWABLE may increase susceptibility to infection, including demodicosis, and exacerbation of neoplastic conditions (see Precautions, Adverse Reactions, Post-Approval Experience and Animal Safety).\nNew neoplastic conditions (benign and malignant) were observed in dogs treated with oclacitinib film-coated tablets (FCT) during clinical studies and have been reported in the post-approval period (see Adverse Reactions and Post-Approval Experience).\nConsider the risks and benefits of treatment prior to initiating APOQUEL CHEWABLE in dogs with a history of recurrent serious infections or recurrent demodicosis or neoplasia (see Adverse Reactions, Post-Approval Experience, and Animal Safety).\nKeep APOQUEL CHEWABLE in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.","apoquel chewable",{"id":68,"kind":64,"statement":69,"species":11,"limitation":11,"source_label":45},15999,"APOQUEL is not for use in dogs less than 12 months of age (see Animal Safety).\nAPOQUEL modulates the immune system.\nAPOQUEL is not for use in dogs with serious infections.\nAPOQUEL may increase susceptibility to infection, including demodicosis, and exacerbation of neoplastic conditions (see Precautions, Adverse Reactions, Post-Approval Experience and Animal Safety).\nNew neoplastic conditions (benign and malignant) were observed in dogs treated with APOQUEL during clinical studies and have been reported in the post-approval period (see Adverse Reactions and Post-Approval Experience).\nConsider the risks and benefits of treatment prior to initiating APOQUEL in dogs with a history of recurrent serious infections or recurrent demodicosis or neoplasia (see Adverse Reactions, Post-Approval Experience, and Animal Safety).\nKeep APOQUEL in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.",{"id":71,"kind":64,"statement":72,"species":11,"limitation":11,"source_label":45},16000,"This product is not for human use. Keep this and all drugs out of reach of children. For use in dogs only. Wash hands immediately after handling the tablets. In case of accidental eye contact, flush immediately with water or saline for at least 15 minutes and then seek medical attention. In case of accidental ingestion, seek medical attention immediately.",{"id":74,"kind":75,"statement":76,"species":11,"limitation":11,"source_label":66},16001,"adverse_reaction","The safety of APOQUEL CHEWABLE was established by pharmacokinetic data comparing oclacitinib film-coated tablets to APOQUEL CHEWABLE (see Clinical Pharmacology).",[],[],[80],{"id":81,"documentId":82,"slug":83,"title":84},116,"gx0rf6pbk00x5p9rlai2h5p7","atopic-dermatitis","Atopic dermatitis",[86],{"id":87,"documentId":88,"slug":89,"name_en":90,"name_ar":11},1414,"rvkmhyozs6s1tlfu4ehuopce","dog","Dog"]